

**National Institute of Clinical Excellence**

**Docetaxel for the treatment of hormone-refractory metastatic prostate cancer**

---

**Royal College of Nursing**

---

**Annie Young (Nurse Director, 3 Counties Cancer Network)**

---

Thank you for the opportunity to submit evidence.

There is nothing further to be submitted by way of evidence, which is not already obtainable via systematic reviews and literature searches, i.e. the two Randomised Controlled Trials, published in the New England Journal of Medicine in November 2004.

It is suggested that the assessment of the technology include a critical review of nursing implications of administering chemotherapy, extra chemotherapy requires extra nursing time.